Anti-SMAD7 (N-terminal) antibody produced in rabbit
SIGMA/SAB4200346 - ~1.0 mg/mL, affinity isolated antibody, suitable for western blot: 2 μg/mL
Synonym: Anti-CRCS3; Anti-MAD homolog 7; Anti-MAD homolog 8; Anti-MADH7; Anti-MADH8; Anti-Mothers against DPP homolog 7; Anti-Mothers against DPP homolog 8; Anti-SMAD
Product Type: Chemical
Immunofluorescence Human A549 cells were fixed and permeabilized with 4% paraformaldehyde followed by 0.5% Triton X-100. Fixed cells were stained with 2.5 μg/mL Rabbit Anti-SMAD7 (N-terminal) (Cat. No. SAB4200346). The antibody was developed using Goat Anti-Rabbit IgG, Cy3 conjugate.
Immunoblotting Whole extract of HEK-293T cells overexpressing human SMAD7 was separated on SDS-PAGE and probed with Rabbit Anti-SMAD7 (N-Terminal) (Cat. No. SAB4200346). The antibody was developed using Goat Anti-Rabbit IgG-Peroxidase (Cat. No. A0545) and a chemiluminescent substrate. Lanes 1. 4 μg/mL antibody 2. 2 μg/mL antibody 3. 2 μg/mL antibody + SMAD7 (N-terminal) immunizing peptide
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| biological source | rabbit |
| clone | polyclonal |
| concentration | ~1.0 mg/mL |
| conjugate | unconjugated |
| form | buffered aqueous solution |
| mol wt | antigen ~46 kDa |
| Quality Level | 200  |
| shipped in | dry ice |
| species reactivity | human |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | indirect immunofluorescence: 1-2 μg/mL using human A549 cells. |
| western blot: 2-4 μg/mL using whole extracts of HEK-293 cells over-expressing human SMAD7. | |
| UniProt accession no. | O15105  |
| Application: | Anti-SMAD7 (N-terminal) antibody produced in rabbit has been used in immunoblotting and immunofluorescence. |
| Biochem/physiol Actions: | SMAD7 (mothers against decapentaplegic homolog 7) is a modulator of TGFβ (transforming growth factor β) signaling in immune cells which are associated with ulcerative colitis and inflammatory bowel syndrome. It plays a major role in the etiology of CRC (colorectal cancer). In addition, it also acts as a mediator of the negative feedback loop for both the TGFβ and BMP (bone morphogenetic proteins) signaling pathways. It is essential for the remodelling of pharyngeal artery and the enlargement of great vessel. In mouse, homozygous removal of Smad7 causes primarily fourth-related arch artery defects. Silencing of Smad7 in RCD (refractory coeliac disease) biopsy samples can decrease the expression of interleukin-6 and tumour necrosis factor-α. Polymorphism of this gene is associated with colorectal cancer. SMAD7 is an inhibitor of the TGFβ (transforming growth factor beta) /BMP (bone morphogenetic proteins) pathway. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| General description: | SMAD7 (mothers against decapentaplegic homolog 7), that binds the E3 ubiquitin ligase Smurf1/2. SMAD7 belongs to the family of inhibitory Smads (I-Smads). |
| Immunogen: | peptide corresponding to the N-terminal region of human SMAD7, conjugated to KLH. The corresponding sequence is identical in monkey and differs by 2 amino acids in mouse and rat. |
| Physical form: | Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide. |
| RIDADR | NONH for all modes of transport |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |